Fundamentally alter the course of osteoarthritis.
LithoLexal® JOINT-FLEX PRO with Vercilexal® helps reduce inflammation and replenish degraded cartilage through Proteoglycan Replacement Therapy to fight both the symptoms and root causes of osteoarthritis.
In a randomised placebo-controlled trial, participants receiving LithoLexal® JOINT-FLEX PRO showed a 143% improvement in WOMAC scores, which measure pain, stiffness, and physical function in osteoarthritis patients.
A comprehensive approach to osteoarthritis.
In addition to targeting the inflammation pathways that worsen osteoarthritis, LithoLexal® JOINT-FLEX PRO is enriched with specific cartilage proteoglycans, to target the root causes of osteoarthritis. It replenishes degraded cartilage and reverses the imbalanced Cartilage Remodelling Cycle.
“Evidence shows that an initial step in cartilage degradation is a decrease in the density of proteoglycans, which is at least partly ‘reversible’.”
Conventional therapies for osteoarthritis include analgesics, anti-inflammatory medications (NSAIDS), and even opioids like tramadol or corticosteroids. However, these do not suppress the underlying inflammation responsible for joint degradation common in osteoarthritis – and they can present safety concerns with long-term use.
In clinical studies, LithoLexal® JOINT-FLEX PRO facilitated a significant reduction in the need for NSAIDs by osteoarthritic patients, allowing for a 50% decrease in daily NSAID use while maintaining or improving joint function and pain management.
© LithoLexal® JOINT-FLEX PRO. ALL RIGHTS RESERVED. LithoLexal® is a brand from Nordic Medical.
Read the LithoLexal.com/joint-flex-pro Terms & Conditions and Privacy Policy.